Staphylokinase, Recombinant, Human

Recombinant Human Staphylokinase is a non-glycosylated polypeptide chain having a molecular weight of 15.5kD.\n\nBiological Activity:\nStaphylokinase is fully biologically active when compared to standard. The biological activity measured by the ability of fibrin lysis in agarose plate was found to be ~4600IU/mg.\n\nSequence:\nThe sequence of the first five N-terminal amino acids was determined and was found to be Ser-Ser-Ser-Phe-Asp.\n\nDimers and Aggregates:\n(same/less than) 1% as determined by silver-stained SDS-PAGE gel analysis.\n\nEndotoxin:\n(same/less than) 0.1ng/ug (IEU/ug) of Human Staphylokinase.\n\nProtein Content:\nProtein quantitation was carried out by two independent methods: \n1. UV spectroscopy at 280nm. \n2. Analysis by RP-HPLC, using a calibrated solution of Staphylokinase as a Reference Standard.\n\nReconstitution:\nReconstitute the lyophilized Human SAK in sterile 18MO-cm H2O not less than 100ug/ml, which can then be further diluted to other aqueous solutions.\n\nStorage and Stability:\nLyophilized powder may be stored at 4 degrees C for short-term only. Reconstitute to nominal volume by adding sterile dH2O and store at -20 degrees C. Reconstituted product is stable for 12 months at -20 degrees C. For maximum recovery of product, centrifuge the original vial prior to removing the cap. Further dilutions can be made in assay buffer.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

S7966

Size

20ug

Form

Supplied as a lyophilized powder in 20mM phosphate buffer, pH 7.0.

Purity

(same/more than) 98% by RP-HPLC, FPLC, or reducing/non-reducing SDS-PAGE Silver Stain. Chromatographically purified.

References

1. Preliminary crystallographic study on a low molecular weight form of bacterial plasminogen activator staphylokinase. Chattopadhyay D, Acta Crystallogr D Biol Crystallogr 1997 Jul;53(Pt 4):480-1 2. Crystallization and preliminary X-ray diffraction studies of reco mbinant staphylokinase. Zhan C, Acta Crystallogr D Biol Crystallogr 1996 May;52(Pt 3):564-5 3. Construction and characterization of novel staphylokinase variants with antiplatelet aggregation activity and reduced immunogenecity. Su HB, Zhang YG, Mo W, Acta Biochim Biophys Sin (Shanghai) 2004 May;36(5):336-42 4. Human alpha -defensins neutralize fibrinolytic activity exerted by staphylokinase. Bokarewa M, Tarkowski A, Thromb Haemost 2004 May;91(5):991-9 5. alpha Domain deletion converts streptokinase into a fibrin-dependent plasminogen activator through mechanisms akin to staphylokinase and tissue plasminogen activator. Sazonova IY, Robinson BR, Castellino FJ, J Biol Chem 2004 Jun 11;279(24):24994-5001 6. Staphylococcus aureus resists human defensins by production of staphylokinase, a novel bacterial evasion mechanism. Jin T, Bokarewa M, Mitchell J, J Immunol 2004 Jan 15;172(2):1169-76.